Angiotensin I (Human, Mouse, Rat) Mechanisms, Clinical Appli

Angiotensin I (Human, Mouse, Rat): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Angiotensin I is a decapeptide precursor in the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis in mammals. The peptide sequence for human, mouse, and rat Angiotensin I is highly conserved, enabling cross-species research and translational studies (Kumar et al., 2019, Front. Physiol.). Angiotensin I itself is biologically inactive but serves as the substrate for angiotensin-converting enzyme (ACE), which cleaves it to form the potent vasoconstrictor Angiotensin II. This conversion is central to the pathophysiology of hypertension, heart failure, and renal diseases (Fyhrquist & Saijonmaa, 2008, J. Intern. Med.).

The availability of synthetic Angiotensin I peptides for human, mouse, and rat models, such as those provided by APExBIO Technology LLC, has enabled precise investigation of RAS dynamics in both basic and translational research. This paper reviews the mechanism of action, clinical value, experimental data, and best practices for using Angiotensin I in research, with a focus on its role in addressing key challenges in cardiovascular and renal therapeutics.

[Related: bleomycin price] Clinical Value and Applications
The clinical value of Angiotensin I lies primarily in its role as a precursor to Angiotensin II, which exerts profound effects on vascular tone, aldosterone secretion, and sympathetic nervous system activity. By modulating the RAS, Angiotensin I and its downstream metabolites are implicated in the pathogenesis and treatment of hypertension, chronic kidney disease, and heart failure (Paul et al., 2006, Circ. Res.).

In clinical research, exogenous Angiotensin I is used to assess ACE activity, evaluate the efficacy of ACE inhibitors, and model RAS-related pathologies in animal studies. For instance, the Angiotensin I infusion test is a diagnostic tool for evaluating the functional status of the RAS in hypertensive patients (Sealey et al., 1980, Hypertension). In preclinical studies, administration of Angiotensin I in rodent models allows for the investigation of genetic and pharmacological interventions targeting the RAS (Crowley et al., 2006, Hypertension).

[Related: aprotinin protease inhibitor] Furthermore, Angiotensin I serves as a substrate in enzymatic assays to screen for novel ACE inhibitors, which are cornerstone therapies for hypertension and heart failure. Its use in such assays facilitates the discovery and optimization of new therapeutic agents (Bernstein et al., 2018, Hypertension).

Key Challenges and Pain Points Addressed
Despite advances in RAS-targeted therapies, several challenges persist in the management of cardiovascular and renal diseases. These include incomplete RAS blockade, variability in patient response, and the emergence of resistance to ACE inhibitors or angiotensin receptor blockers (ARBs) (Burnier & Brunner, 2000, Hypertension).

[Related: rsl3 drug] Angiotensin I peptides address these challenges in several ways:
- **Standardization of Research Models:** Synthetic Angiotensin I enables reproducible in vitro and in vivo studies across species, facilitating the comparison of genetic and pharmacological interventions.
- **Assessment of ACE Activity:** By serving as a substrate in biochemical assays, Angiotensin I allows for precise measurement of ACE activity and inhibitor potency, supporting drug development and therapeutic monitoring.
- **Elucidation of RAS Pathophysiology:** Exogenous administration of Angiotensin I in animal models helps dissect the contributions of various RAS components to disease phenotypes, guiding the development of more targeted interventions.
- **Overcoming Species Differences:** The availability of species-specific Angiotensin I peptides (human, mouse, rat) ensures that experimental findings are relevant and translatable, minimizing confounding due to interspecies sequence variation.

Literature Review
Several key studies have elucidated the role of Angiotensin I in health and disease, as well as its utility in research and drug development:

1. **Fyhrquist & Saijonmaa (2008, J. Intern. Med.)** provided a comprehensive overview of the RAS, highlighting the central role of Angiotensin I as a precursor to Angiotensin II and its implications in cardiovascular regulation.

2. **Crowley et al. (2006, Hypertension)** demonstrated the use of Angiotensin I infusion in genetically modified mice to investigate the contributions of ACE and Angiotensin II receptors to blood pressure regulation and end-organ damage.

3. **Sealey et al. (1980, Hypertension)** described the Angiotensin I infusion test as a clinical tool for assessing RAS activity in hypertensive patients, establishing its diagnostic value.

4. **Paul et al. (2006, Circ. Res.)** reviewed the therapeutic potential of RAS modulation, emphasizing the importance of understanding Angiotensin I metabolism for optimizing ACE inhibitor therapy.

5. **Bernstein et al. (2018, Hypertension)** discussed advances in ACE inhibitor development, noting the critical role of Angiotensin I as a substrate in screening and characterizing novel compounds.

6. **Kumar et al. (2019, Front. Physiol.)** explored the evolutionary conservation of Angiotensin I across species, supporting its use in translational research.

7. **Burnier & Brunner (2000, Hypertension)** addressed the limitations of current RAS inhibitors and the need for improved models and assays, many of which rely on synthetic Angiotensin I peptides.

Collectively, these studies underscore the foundational role of Angiotensin I in both basic and applied research, as well as its clinical relevance.

Experimental Data and Results
Experimental studies employing Angiotensin I have provided critical insights into RAS function and pharmacology. For example, Crowley et al. (2006) infused Angiotensin I into wild-type and genetically modified mice, observing dose-dependent increases in blood pressure that were abrogated by ACE inhibition. This established the dependence of Angiotensin I-induced hypertension on ACE activity and Angiotensin II formation.

In enzymatic assays, Angiotensin I is used to quantify ACE activity in plasma or tissue extracts. Bernstein et al. (2018) reported that the rate of Angiotensin II generation from Angiotensin I correlates with ACE expression and can be inhibited by clinically relevant ACE inhibitors such as captopril and enalapril. These findings validate the use of Angiotensin I as a functional readout for ACE activity and inhibitor efficacy.

In clinical settings, Sealey et al. (1980) demonstrated that the Angiotensin I infusion test could differentiate between low-renin and high-renin forms of hypertension, guiding personalized therapy. The test involves intravenous administration of Angiotensin I and measurement of blood pressure response, providing a functional assessment of RAS integrity.

Additionally, studies in rodent models have shown that chronic Angiotensin I infusion induces cardiac and renal hypertrophy, mimicking human disease phenotypes and enabling the evaluation of novel therapeutic interventions (Paul et al., 2006). These models are instrumental in preclinical drug development and mechanistic studies.

Usage Guidelines and Best Practices
The effective use of Angiotensin I in research requires careful consideration of peptide purity, dosing, and experimental context. The following guidelines are recommended:

- **Peptide Quality:** Use high-purity (>95%) synthetic Angiotensin I peptides, validated for sequence and mass, to ensure reproducibility and minimize confounding effects from impurities.
- **Species Specificity:** Select the appropriate Angiotensin I sequence (human, mouse, or rat) based on the experimental model to avoid cross-reactivity and ensure physiological relevance (Kumar et al., 2019).
- **Storage and Handling:** Store lyophilized peptides at -20°C or below, and reconstitute in sterile, buffered solutions immediately prior to use. Avoid repeated freeze-thaw cycles.
- **Dosing and Administration:** For in vivo studies, dosing regimens should be based on published protocols, typically ranging from 10 to 1000 ng/kg/min for infusion studies in rodents (Crowley et al., 2006). In vitro assays may use concentrations from 0.1 to 10 μM, depending on the assay sensitivity.
- **Controls and Validation:** Include appropriate negative controls (vehicle or scrambled peptide) and positive controls (known ACE inhibitors) to validate assay specificity.
- **Ethical Considerations:** All animal studies should be conducted in accordance with institutional and national guidelines for the care and use of laboratory animals.

Future Research Directions
Despite significant progress, several avenues for future research remain:

- **Novel RAS Modulators:** The development of next-generation ACE inhibitors, Angiotensin II receptor antagonists, and alternative pathway modulators will benefit from improved in vitro and in vivo models using Angiotensin I as a substrate.
- **Biomarker Discovery:** Quantitative assays using Angiotensin I may Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406